Phase I Trial of Sunitinib Malate plus Interferon-α for Patients with Metastatic Renal Cell Carcinoma

BACKGROUND: Sunitinib malate is an oral, multitargeted tyrosine kinase inhibitor that has demonstrated superior efficacy over interferon (IFN)–α in a phase III trial in first-line, metastatic renal cell carcinoma (RCC). Herein, we report the results of a phase I dose-finding study of sunitinib in co...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Motzer, Robert J., Hudes, Gary, Wilding, George, Schwartz, Lawrence H., Hariharan, Subramanian, Kempin, Susan, Fayyad, Rana, Figlin, Robert A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2009
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3394091/
https://ncbi.nlm.nih.gov/pubmed/19213665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3816/CGC.2009.n.005
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi